Arcani Robin, Ambrosi Pierre
Laboratory of Therapeutics and the Aix-Marseille Universite, Marseille, France.
Cardiac Transplant Unit, La Timone Hospital, Aix-Marseille University, Marseille, France.
Clin Transplant. 2025 May;39(5):e70190. doi: 10.1111/ctr.70190.
We previously reported a high level of seroconversion 1 year after COVID-19 vaccination in heart transplant recipients when vaccination was performed several years after transplantation. The aim of this study was to measure the seroconversion rate late after vaccination, in the absence of a new vaccine injection. We included 37 patients vaccinated in 2021. We measured immunoglobulin response using TrimericS Diasorin assay at the last visit between October 2024 and February 2025. We found a seroconversion rate of 95%, 3.2 ± 0.13 years after last COVID-19 vaccination in the absence of new vaccine injection. Most of these patients (73%) had a proven COVID-19 infection since vaccination. Interestingly, none of these patients had a severe form of COVID-19. Thus, vaccination, followed by minor COVID-19 infections, effectively prevented severe forms.
我们之前报道过，心脏移植受者在移植数年之后接种新冠疫苗，1年后血清转化率很高。本研究的目的是在未接种新疫苗的情况下，测量接种疫苗后较长时间的血清转化率。我们纳入了2021年接种疫苗的37例患者。在2024年10月至2025年2月的最后一次随访中，我们使用TrimericS Diasorin检测法测量免疫球蛋白反应。我们发现，在未接种新疫苗的情况下，自最后一次接种新冠疫苗3.2±0.13年后，血清转化率为95%。这些患者中的大多数（73%）自接种疫苗后确诊感染过新冠病毒。有趣的是，这些患者中没有一人患重症新冠。因此，接种疫苗后再经历轻症新冠感染，能有效预防重症。
